Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2003
10/16/2003WO2003084941A2 Hydroxamic acid derivatives
10/16/2003WO2003084940A1 Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors
10/16/2003WO2003084938A2 Pyrimidone derivatives useful for the treatment of inflammatin and immunological diseases
10/16/2003WO2003084937A2 Pyrimidinedione derivatives useful for the treatment of inflammation and immunological diseases
10/16/2003WO2003084936A2 Amino substituted pyrimidinone derivatives useful in the treatment of inflammation and immunological
10/16/2003WO2003084935A2 Diaryl pyrimidinone derivatives useful for the treatment of inflammation and immunogolical diseases
10/16/2003WO2003084928A1 Alpha, omega-dicarboximide derivatives as useful uro-selective α1α adrenoceptor blockers
10/16/2003WO2003084926A2 Polymeric acyl derivatives of indoles
10/16/2003WO2003084916A2 Compounds that modulate ppar activity and methods for their preparation
10/16/2003WO2003084611A1 Depsipeptide for therapy of kidney cancer
10/16/2003WO2003084582A1 Embolization
10/16/2003WO2003084574A1 Multivalent constructs for therapeutic and diagnostic applications
10/16/2003WO2003084570A1 DRUG CONTAINING ANTIBODY COMPOSITION APPROPRIATE FOR PATIENT SUFFERING FROM FcϜRIIIa POLYMORPHISM
10/16/2003WO2003084569A1 Drug containing antibody composition
10/16/2003WO2003084561A1 Use of long pentraxin ptx3 for the treatment of fgf-8 mediated tumour diseases
10/16/2003WO2003084549A1 Hormone replacement therapy
10/16/2003WO2003084543A1 Combination of glivec(sti571) with a cyclin-dependent kinase inhibitor, especially flavopiridol in the treatment of cancer
10/16/2003WO2003084533A1 N-`4-(2-imino-pyrrolidin-1-yl)phenyl!-acetamide and corresponding piperidine derivatives as factor xa inhibitors for the treatment of thrombo-embolic diseases
10/16/2003WO2003084531A1 Vitamin combination for providing protection during the chemotherapy and/or radiotherapy of malignant tumours
10/16/2003WO2003084529A2 Low-pressure mercury vapor discharge lamp
10/16/2003WO2003084527A1 Severe sepsis preventive therapeutic agent
10/16/2003WO2003084521A2 Use of conjugated estrogens in combination with trimegestone in hormone replacement therapy
10/16/2003WO2003084464A2 Benzopyran derivatives substituted with secondary amines including tetrazole, method for the preparation thereof and pharmaceutical compositions containing them
10/16/2003WO2003084344A2 Method of improving absorption of vitamin e by a pet animal
10/16/2003WO2003084343A2 Method and dietary composition for improving fat digestibility
10/16/2003WO2003084342A2 Method and dietary composition for improving lipid digestibility
10/16/2003WO2003084305A2 Trihydroxy polyunsaturated eicosanoids
10/16/2003WO2003084302A2 Anti-aging agent
10/16/2003WO2003070701A3 Syntheses of quinazolinones
10/16/2003WO2003068954A3 Microorganism for genetic therapeutic treatment of proliferative diseases
10/16/2003WO2003068809A3 An herpes simplex virus complex
10/16/2003WO2003063792A8 Compositions and methods related to tim-3, a th1-specific cell surface molecule
10/16/2003WO2003062826A3 Materials and methods for examining and treating nasopharyngeal carcinoma
10/16/2003WO2003062276A3 Multimers of receptor-binding ligands
10/16/2003WO2003059282A3 Human monoclonal antibodies against cd30
10/16/2003WO2003057729A3 Mammal prolactin variants
10/16/2003WO2003054216A3 Antibodies that immunospecifically bind to trail receptors
10/16/2003WO2003051905A3 Taojiks as modifiers of the beta-catenin pathway and methods of use
10/16/2003WO2003050064A3 Mitotic kinesin inhibitors
10/16/2003WO2003046560B1 Self-assembly molecules
10/16/2003WO2003045952A3 Condensed camptothecins as antitumor agents
10/16/2003WO2003045414A3 Use of laminarin in the treatment of cancer as well as bacterial, viral and fungal infections
10/16/2003WO2003041660A3 Solubilized topoisomerase poisons
10/16/2003WO2003037314A3 Medical compositions for intravesical treatment of bladder cancer
10/16/2003WO2003035835A3 Glycoprotein compositions
10/16/2003WO2003034069A3 Tcmp 03 protein for use in cancer therapy
10/16/2003WO2003033660A3 9136, a human aldehyde dehydrogenase family member and uses therefor
10/16/2003WO2003030814A3 Cross-regulin composition of turmeric-derived tetrahydrocurcuminoids for skin lightening and protection against uvb rays
10/16/2003WO2003029434A3 Novel molecules of the hkid-1-related protein family and uses thereof
10/16/2003WO2003028634A3 Method of treatment using ligand-immunogen conjugates
10/16/2003WO2003025127A3 Chromogenic in situ hybridization methods, kits, and compositions
10/16/2003WO2003024993A3 Measuring circulating therapeutic antibody, antigen and antigen/antibody complexes using elisa assays
10/16/2003WO2003022260B1 Use of methotrexate and l-arginine for the preparation of a medicament for treatment of uterine myoma
10/16/2003WO2003016472A3 Hybrid interferon/interferon tau proteins, compositions and methods of use
10/16/2003WO2003015707A3 Method for treating lung cancers
10/16/2003WO2003011907A3 Receptor, the use thereof, and mouse antibodies
10/16/2003WO2003011342A3 Targeted polymeric delivery systems
10/16/2003WO2003011314A3 Use of lhrh-antagonists for the improvement of t-cell mediated immunity
10/16/2003WO2003011211A3 Peg-modified uricase
10/16/2003WO2003010192A3 An inducer of apoptosis
10/16/2003WO2003008407A3 Phenylsulfonyl-1,3-dihydro-2h-indole-2-one derivatives, their preparation and their therapeutic use
10/16/2003WO2003006055A9 Methods for promoting antigen presentation and modulating immune responses using cholera toxin and its b subunit
10/16/2003WO2003005036A3 Epf receptor assays, compounds and therapeutic compositions
10/16/2003WO2002102307A3 Nucleoside vaccine adjuvants
10/16/2003WO2002100849A3 Novel nitriles useful as reversible inhibitors of cysteine proteases
10/16/2003WO2002100826A3 Substituted 3-aryl-5-aryl-[1,2,4]-oxadiazoles and analogs
10/16/2003WO2002099043A3 P5CRS AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
10/16/2003WO2002098899A3 CHDs AS MODIFIERS OF THE p53 PATHWAY AND METHODS OF USE
10/16/2003WO2002097043A3 Wnv core protein/capsid interacting protein and uses of the same
10/16/2003WO2002088081A3 Wnt and frizzled receptors as targets for immunotherapy in head and neck squamous cell carcinomas
10/16/2003WO2002085299A3 Therapeutic treatments using the direct application of antimicrobial metal compositions
10/16/2003WO2002076939A3 Cysteine protease inhibitors
10/16/2003WO2002072009A3 Heterocyclic derivatives for the treatment of cancer and other proliferative diseases
10/16/2003WO2002068677A8 Novel methods of diagnosis of metastatic colorectal cancer, compositions and methods of screening for modulators of metastatic colorectal cancer
10/16/2003WO2002064134A3 Use of calcium indomethacin for the treatment of cyclo-oxygenase 2-mediated pathologies
10/16/2003WO2002060887A3 Synthesis of 4h-chromene derivatives
10/16/2003WO2002054064A3 Method for screening for progesterone receptor isoform-specific ligands
10/16/2003WO2002044384A3 T-cell epitope of the papillomavirus l1 and e7 protein and use thereof in diagnostics and therapy
10/16/2003WO2002042484A3 Method for producing pectin hydrolysis products
10/16/2003WO2002007739A9 Pharmaceutical preparation for the treatment and diagnosis of tumors and method for the preparation of the lipid free fraction of blood plasma
10/16/2003WO2002007673A3 Calcilytic compounds
10/16/2003US20030196217 Desaturase genes, enzymes encoded thereby, and uses thereof
10/16/2003US20030195377 Cycloalkyl substituted polyamines for cancer therapy and methods of synthesis therefor
10/16/2003US20030195365 CC-1065 analog synthesis
10/16/2003US20030195362 For therapy of retroviral infection and in particular an HIV infection
10/16/2003US20030195360 For therapy of oncoses
10/16/2003US20030195337 UL16 binding protein 4
10/16/2003US20030195250 Method for photodynamic therapy and applicator for carrying out said therapy
10/16/2003US20030195241 Mitogen-activated protein kinase inhibitors used for prophylaxis of cancer, inflammatory and cardiovascular disorders, and as coatings for medical equipments such as stents
10/16/2003US20030195238 Enzyme inhibitors
10/16/2003US20030195236 Heterocyclic imines such as 2-methyl-3-toluoyloxy-4-formyl-5-hydroxymethylpyridine, used for prophylaxis of vitamin B6 deficiency, cardiovascular disorders or melanomas
10/16/2003US20030195234 Substituted oxindole derivatives as tyrosine kinase inhibitors
10/16/2003US20030195230 Substituted amine derivatives and methods of use
10/16/2003US20030195225 Acidification of drugs such as carbendazim, by mixing with buffers improving water solubility; anticarcinogenic agents
10/16/2003US20030195224 An immunomodulators, antitumor agents and induce cytokine biosynthesis, treating viral diseases
10/16/2003US20030195222 Substituted pyrimidinones and pyrimidinthiones
10/16/2003US20030195221 Substituted indolizine-like compounds and methods of use
10/16/2003US20030195214 Cancer treatment
10/16/2003US20030195212 An amide derivatives for treating obesity, anorexia, inflammation, mental diseases associated with the melanocyte stimulating hormones
10/16/2003US20030195202 Inhibitors of IMPDH enzyme
1 ... 1500 1501 1502 1503 1504 1505 1506 1507 1508 1509 1510 1511 1512 1513 1514 1515 1516 1517 1518 1519 1520 ... 2211